Skip to main content
CODX
NASDAQ Industrial Applications And Services

Co-Diagnostics Advances Flu/RSV Test Toward FDA Clearance and Names New CSO

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.47
Mkt Cap
$10.401M
52W Low
$1.26
52W High
$46.5
52W Position info
17% above low
Off High info
97% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

CODX sits 17% above its 52-week low of $1.26 on light trading volume (0.1× avg).

Summary

Co-Diagnostics submitted an FDA 510(k) for its Flu/RSV test and appointed a new CSO, while reporting a $6.3M quarterly loss and $3.6M cash balance.


Key Events · Earnings and Guidance · CODX

  • FDA 510(k) Submission

    Submitted 510(k) premarket notification with concurrent CLIA Waiver by Application for Co-Dx PCR Flu A/B & RSV test on Co-Dx PCR Pro instrument.

  • New Chief Scientific Officer

    Appointed Wes Lindsey, Ph.D., MBA, as CSO to lead scientific and regulatory strategy, including FDA submissions.

  • Q2 Financial Results

    Net loss of $6.3 million ($1.46 per share) on revenue of $0.17 million; cash and equivalents of $3.6 million as of June 30, 2026.

  • International Clinical Progress

    Initiated clinical performance studies in India for CoSara PCR MTB test; advanced Bundibugyo virus assay development.


Analysis · CODX · Industrial Applications And Services

The second quarter brought a net loss of $6.3 million and a cash position of just $3.6 million, but the more consequential development is the FDA 510(k) submission for the Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument, accompanied by a concurrent CLIA Waiver by Application. This represents a pivotal regulatory step toward commercializing the company's point-of-care molecular diagnostics platform. To steer scientific and regulatory strategy, including FDA submissions, the company appointed Wes Lindsey, Ph.D., MBA, as Chief Scientific Officer. Clinical studies for its tuberculosis test also commenced in India. With a going concern warning and critical cash burn, these regulatory and operational moves are essential for the company's survival and future revenue generation.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CODX was trading at $1.47 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $1.26 to $46.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CODX - Latest Insights

CODX
Nov 13, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2585
Real-time Price: $0.2332 info
Change: -$0.0253 (-10%) info
Market Cap: $2.718M info
CODX
Nov 10, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.2856
Real-time Price: $0.2332 info
Change: -$0.0524 (-18%) info
Market Cap: $2.718M info
CODX
Nov 10, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.3652
Real-time Price: $0.2332 info
Change: -$0.132 (-36%) info
Market Cap: $2.718M info
CODX
Nov 04, 2026, 4:45 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $0.3615
Real-time Price: $0.2332 info
Change: -$0.1283 (-35%) info
Market Cap: $2.718M info
CODX
Oct 26, 2026, 4:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.5459
Real-time Price: $0.2332 info
Change: -$0.3127 (-57%) info
Market Cap: $2.718M info